Skip to main content

Table 1 Patients` characteristics

From: Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis

CharacteristicNumber of patients absolute relative
Sex
 Female1139.3%
 Male1760.7%
Karnofsky performance status (KPS)
 90–100%2278.6%
 80%517.9%
 70%13.6%
BRAF Status
 BRAF V600-E-Mutation1450.0%
 No BRAF V600-E-Mutation1450.0%
Controlled extracranial disease
 Yes1035.7%
 No1864.3%
RPA class
 1621.4%
 22278.6%
 300%
Melanoma-molGPA
 0.5–1.027.1%
 1.5–2.01139.3%
 2.5–3.01139.3%
 3.5–4.0414.3%
Number of SRS lesions per patient
 11346.4%
 2725.0%
 3725.0%
 413.6%
Whole brain radiotherapy
 Yes414.3%
Before first SRS13.6%
After first SRS310.7%
 No2485.7%
Targeted/ immunotherapy (TT/IT)
 BRAFi (Dabrafenib/ Vemurafenib)
 MEKi (Trametinib)
2
1
7.1%
3.6%
 Anti-CTLA-4 (Ipilimumab)27.1%
 Anti-PD1 (Nivolumab/Pembrolizumab)621.4%
 BRAFi+MEKi (Dabrafenib-Trametinib/ Encorafenib-Binimetinib)310.7%
 BRAFi+MEKi ➔ Anti-PD113.6%
 Anti-PD1 + Anti-CTLA-4 (Nivolumab-Ipilimumab)725.0%
 BRAFi+MEKi ➔Triple combination (Pembrolizumab-Dabrafenib-Trametinib)13.6%
none517.9%
Concurrent TT/IT
 Yes2071.4%
 No828.6%